Millennium Management’s Myriad Genetics MYGN Stock Holding History

Millennium Management’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-80,000	Closed	-$710K	–	6178
2025 Q1	$710K	Sell	80,000 -190,000	-70%	-$2.28M	﹤0.01%	4598
2024 Q4	$3.7M	Buy	+270,000	New	+$4.98M	﹤0.01%	3103
2024 Q3	–	Sell	-30,000	Closed	-$734K	–	6341
2024 Q2	$734K	Sell	30,000 -190,000	-86%	-$4.17M	﹤0.01%	4336
2024 Q1	$4.69M	Buy	220,000 +120,000	+120%	+$2.58M	﹤0.01%	2924
2023 Q4	$1.91M	Sell	100,000 -143,900	-59%	-$2.49M	﹤0.01%	3648
2023 Q3	$3.91M	Buy	+243,900	New	+$4.64M	﹤0.01%	2940
2023 Q2	–	Sell	-20,400	Closed	-$474K	–	6495
2023 Q1	$474K	Buy	+20,400	New	+$414K	﹤0.01%	4642
2022 Q4	–	Sell	-20,300	Closed	-$387K	–	6872
2022 Q3	$387K	Sell	20,300 -121,500	-86%	-$2.79M	﹤0.01%	5175
2022 Q2	$2.58M	Sell	141,800 -8,200	-5%	-$170K	﹤0.01%	3442
2022 Q1	$3.78M	Sell	150,000 -95,000	-39%	-$2.43M	﹤0.01%	3233
2021 Q4	$6.76M	Buy	+245,000	New	+$7.1M	﹤0.01%	2587
2017 Q3	–	Sell	-150,000	Closed	-$3.88M	–	3736
2017 Q2	$3.88M	Buy	+150,000	New	+$3.18M	0.01%	1677
2017 Q1	–	Sell	-150,000	Closed	-$2.5M	–	3722
2016 Q4	$2.5M	Buy	+150,000	New	+$2.71M	0.01%	1754
2014 Q1	–	Sell	-58,800	Closed	-$1.23M	–	3743
2013 Q4	$1.23M	Sell	58,800 -68,000	-54%	-$1.72M	﹤0.01%	2145
2013 Q3	$2.98M	Buy	+126,800	New	+$3.6M	0.01%	1443

Other funds holding MYGN

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

GCM

Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management's MYGN Position: Q1 2026 in Review

Millennium Management reduced its Myriad Genetics (MYGN) stake by 0.47% in Q1 2026, selling an estimated $163K and leaving 6,668,817 shares worth $30M. The position accounts for 0.01% of the portfolio, ranked #1228.

Millennium Management first reported a position in MYGN in Q2 2013 and has held it in 46 quarters since. The position peaked at $142M in Q3 2024. 202 funds tracked by Wall St. Rank hold MYGN as of Q1 2026.

Millennium Management held 6,668,817 shares of Myriad Genetics worth $30M as of Q1 2026.
Millennium Management sold 31,341 Myriad Genetics shares in Q1 2026, an estimated $163K.
Myriad Genetics made up 0.01% of Millennium Management's portfolio in Q1 2026, its #1228 holding.
Millennium Management first reported a position in Myriad Genetics in Q2 2013 and has held it in 46 quarters since.
Millennium Management's Myriad Genetics position peaked at $142M in Q3 2024.
202 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.